HK Stock Market Move | CF PHARMTECH (02652) rose by over 5% after completing the placement of 21.7477 million new H shares. ICF001 is expected to fill the clinical gap in the treatment of PH-ILD.

CF PHARMTECH (02652) rose over 5%, and as of the time of writing, it is up 4.84%, priced at HK$16.89, with a transaction volume of HK$65.3977 million. In the news, CF PHARMTECH announced that it has completed the placement of 21.7477 million new H-shares on August 6, 2026, at a placement price of HK$13.82 per H-share, raising approximately HK$295 million net. According to previous company announcements, about 70% of the net proceeds will be used for the clinical and preclinical development of the group's innovative drug candidates; about 15% will be used for the CMC research, clinical studies, development of delivery devices, and costs related to registration and regulatory filings for the groups complex inhalation formulation products globally (including CF048, CF059/CF060, CF066 EDS, CF067, CF068, and CF011/CF088). It is reported that CF PHARMTECH has established a comprehensive inhalation formulation platform covering R&D, production, and global registration. The company possesses R&D and production capabilities across multiple technological pathways, including nebulizers, aerosols, dry powder inhalers, nasal sprays, inhalation sprays, small nucleic acids, and liposome inhalation delivery, forming a complete progression path from platform construction for multiple dosage forms to original innovation. The clinical trial application for the self-developed new drug ICF001 has been officially accepted by the National Medical Products Administration. Currently, there are no approved specific drugs in the domestic PH-ILD field, and ICF001 is expected to become the first approved inhalation drug for the treatment of PH-ILD in China, filling this clinical gap.